Beyond first-line treatment, in particular for patients with wild type EGFR who have received first-line chemotherapy, recommendations regarding the potential benefits of TKIs are less clear (NICE TA162, NCCN Guidelines for Non–Small-Cell Lung Cancer).6,7. Here, EGFR is linked to small cell lung carcinoma.